RxDoctor Payments Data

Christopher Peterson, MD

Hematology & Oncology · Wausau, WINPI 1700897535

Payments from drug & device makers

$12,005in general payments, 2019–2025

Across 24 payments — averaging $500.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Exelixis Inc.$2K
  • Johnson & Johnson$44
  • AstraZeneca$43
  • Acrotech Biopharma Inc.$38
  • Novartis$28
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$1065%
  • Education$1,89995%

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$10,022
Exelixis Inc.11$1,806
Johnson & Johnson3$44
AstraZeneca1$43
Acrotech Biopharma Inc.3$38
Novartis2$28
Merck1$12
Gilead1$12

How this compares

$12,005 in reported general payments places this provider in the 55th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$80,098
Medicare patients
356
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide131$2,337,524
BrukinsaZanubrutinib87$1,088,088
JakafiRuxolitinib Phosphate53$901,696
CabometyxCabozantinib S-Malate29$739,829
LenvimaLenvatinib Mesylate31$731,829
IbrancePalbociclib31$528,867
PomalystPomalidomide17$408,780
IclusigPonatinib Hcl12$256,179
BraftoviEncorafenib15$250,626
ImbruvicaIbrutinib15$246,714
Lenalidomide15$215,537
AlecensaAlectinib Hcl12$210,725
KisqaliRibociclib Succinate14$209,426
CalquenceAcalabrutinib Maleate12$180,729
VonjoPacritinib Citrate12$154,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$1,806$739,82929 claims
PfizerIbrance, Eliquis$10,022$557,16474 claims
NovartisKisqali, Tasigna$28$316,44225 claims
AstraZenecaCalquence, Lynparza$43$311,50526 claims
Johnson & JohnsonXarelto$44$17,31917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →